Profile Summary

Qualification :

1978 M.B.B.S. Seth G.S. Medical College & K.E.M. Hospital

1982 M.D. K.E.M. Hospital - Medicine & Therapeutics

2012 FACE Fellow American College of Clinical Endocrinology

2015 FACP Fellow of the American College of Physicians

2017 FRCP Fellow of Royal College of Physician Edinburg

2017 FISH Fellow of India Score of Hypertension-India

 

 

Introduction:

Clinical Experience : 

• 1983 onwards Consultant Physician & CardioMetabolic Specialist in Breach Candy Jaslok, Bhatia, and Reliance H. N. Hospitals.
• 1983-1985 Research Associate – (Cardiology & Medicine) Cardio Vascular & Thoracic Centre - K.E.M. Hospital.
• 1990onwards Chief Medical Advisor - Times Of India (Bennett Coleman & Co. Ltd).
• 1992onwards Principal Investigator in more then > 35 studies - Multicentric International and National Clinical studies.
• 1999onwards Consultant Editor – ‘Health’ -Times of India.
• 2001onwards Professor and DNB (Diplomate National Board) Teacher in Internal Medicine at Jaslok Hospital.
• 2001onwards Specialised Educator (Hypertension, Diabetes and Metabolics) - Association of Physicians of India (API), Research Society for the Study in Diabetes In India (RSSDI), Cardiology Society of India (CSI) and numerous National and International associations).
• 2001onwards Steering Committee Member for National Clinical Trials and Projects in Hypertension, Diabetes and Metabolics.
• 2002 onwards Consultant on Cardiovascular Diseases Prevention to Indo-American Society.
• 2003onwards Founder and Chairman of the “South Bombay Physician’s Journal Club” – a Medical Council of India accredited body involved in Post Graduate CME activities.
• 2004onwards DNB examiner and appraiser at different teaching institutes in Mumbai
• 2011onwards Cofounder and Faculty Expert of the “Predieases Forum”- an International initiative with members from all over the world – Launched at the IDF – Dec 2011.
• 2013onwards Lead Investigator and Steering Committee member of a study to Preempt Hypertension and Cardiovascular Morbidity in Indian Metros.
• 2020onwards Advisor to the task force of Mumbai Covid committee. Played a pivotal role
• In personally hands-on admitting, treating and following up Covid patients at Breach Candy, Jaslok and Bhatia hospitals. Besides, helping in protocol formulation, treatment advisories and clinical research for innovative new drugs (has numerous publication to this effect), he played a lead role in guiding the hospital, paramedical staff and the community at large in the pandemic.

 

Academic Honours : 

• 1974 - Principal’s Prize for the Best Student of the year, Jai Hind College.
• 1975 - The Vasant Phansalkar Scholarship and Gold Medal in Pharmacology for standing 1st in Pharmacology at the 2nd M.B.B.S. exam conducted by the Bombay University.
• 1979 - Prize for the Best Intern of Seth G.S. Medical College and K.E.M. Hospital.
• 2010-2011 - Awarded “Key - Note Address” by Indian Medical Association Branch – Mumbai (IMA) at their Annual conference.
• 2012 - Awarded Fellowship of American College of Clinical Endocrinology (FACE) in recognition of meritorious work done in Diabetes and CardioMetabolic disorders.
• 2014 Bestowed the Giants International Award for Outstanding Contribution in the field of Medicine.
• 2015 Awarded Fellowship of the American College of Physicians – FACP
• 2017 Awarded Fellowship of the Royal College of physicians (Glasgow) - FRCP
• 2020 Awarded the best COVID warrior title by the Wockhardt medical foundation.

 

Clinical Research Activities as Principal Investigator :

• Clinical Study of Verapamil 240mg SR (sustained released) in the control of Mild to Moderate Hypertension – 20 cases followed up over 6 months – 1992.
• Dygaid – A clinical experience of a new Antacid, Antiflattulent in cases of mild Clinical Dyspepsia – a 6 month study in 50 cases – paper published in the Bombay Hospital journal Vol.35 No.3. (1995).
• Clinical Efficacy of ascending concentrations of Nicotine Patches in the treatment of cigarette smoking withdrawal - trial conducted on 10 patients on an OPD basis. (1995 – 1996).
• Evaluation of the Antibacterial activity of Levofloxacin in patients hospitalized for Primary Respiratory conditions. Conducted at Jaslok Hospital on 10 patients – trial conducted for Aventis Pharma (1998 – 1999).
• The use of pen-filled insulin in ambulatory patients of Type II Diabetes. A clinical study using Eli Lilly’s Short and Long acting human insulin’s in 10 patients on an OPD basis (2000 – 2001).
• The pioneering study of the efficacy of Chirally pure Amlodipine in Essential Hypertension - a double blind study using chiral and racemic Amlodipine in 20 patients on an outpatient basis (2001-2002).
• The efficacy of Metoprolol in an extended release form – Seloken XL, in Essential Hypertension. A nationwide OPD study of 2000 patients conducted by ASTRA over a period of 6 months (2002).
• The use of Chirally pure Atenolol in the treatment of mild to moderate hypertension in 50 patient. A double blind study spanning 7 months conducted on an OPD basis supervised and sponsored by Emcure Pharma (2002 – 2003).
• The use of purified Fenugreek in lowering sugar levels and increasing insulin secretion on 10 healthy volunteers following repeated glucose challenges – study conducted in conjunction with Innovasynth Technologies (USA) Ltd. – Indian branch (2004).
• A Global study (Gemini ALAA-200 international sites) to determine the Efficacy of Amlodipine and Atorvastatin in combination (Caduet) in patients of Essential Hypertension and Dyslipidemia - 15 patients (2004).
• Double blind study to determine the clinical efficacy of Chirally pure Pantoprozole in comparison with Racemic Pantoprozole- an OPD study of 50 randomised patients (2004-2005).
•  A comparative study of glycaemic control in 70 diabetic patients using disposable pen filled Mixtard Insulin Vs highly purified as part insulin in pen-filled form - 2005
•  A study on 50 patient with Idiopathic Fatty Liver (non viral) using a double blind method to study the efficacy of a coded drug at Bhatia Hospital – sponsor – Charak Pharmaceuticals (2005-2007).
• A double blind study comparing the efficacy of a new coded statin with Atorva - 25 patients conducted at Bhatia Hospital. (2005 – 2008).
• A double blind placebo controlled study comparing the efficacy new DPP4 agent in Type 2 diabetes.(2006 - 2008)
• A Once Daily Dose-Ranging Study of Study drug (DPP4) Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Drug Naïve Subjects. Phase II b (2006 - 2008)
• A double blind, double dummy, parallel-Group international study comparing oral Rivaroxaban with Warfarin for the prevention of stroke in patients with Non -Valvular Atrial Fibrillation. (2006 -2010)
• A Multinational, Multicenter, Randomized, Double-Blind Study Comparing – The Efficacy and Safety of Study drug with Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients with Restricted \ Mobility. (2007 – 2009)
• A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (BotulinumToxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment (2007-2010).
• Randomised Dabigatran Etexilate dose finding study in patients with Acute Coronary Syndromes post index Event with additional risk factors for cardiovascular complications also receiving Aspirin and Clopidogrel: Multi- centre, prospective, placebo controlled, group dose escalation trial. Phase II. (2008-2010).
• A registry to study the switch from existing insulin treatment to another insulin treatment in inadequately controlled Type 1 and Type 2 diabetes patients. (2010-2011)
• Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co morbidities. A randomised, double-blind, placebo controlled, parallel group, multi-centre, multinational trial with stratification of subject to either 56 or 160 weeks of treatment based on pre-diabetes status at randomization. (2010-2015).
• A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia.(2010 - 2013)
• A Multicenter, Randomized, Double blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Algoliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. (2010 – 2014).
• Multinational Observational Study Assessing Insulin use: understanding the challenges associated with progression of therapy - The MOSAIc Type 2 Diabetes Study (2011- 2015).
• A 16 week, randomized, placebo controlled study to evaluate the Efficacy and safety of extended release niacin/Laropiprant in South & Southeast Asians not on Lipid Modulating agent, with decreased High density Lipo-Protein Cholesterol & Low - Density Lipo-Protein Cholesterol at or below NCEP ATP III Goal. (2011-2013).
• A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (2011-2018).
• A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety and Efficacy of PF-04937319 and Sitagliptin on Glycaemic Control in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin. (2011 - 2013)
•  Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes (2014 - 2015)
• A Prospective Double Blind, Placebo-Controlled, Randomized, Multicentric, study to evaluate safety and efficacy of PreCrea®, a twice-daily nutritional supplement in people with higher than normal blood sugar levels. (2014 -2015)
• Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin” Phase: 4 study (2014-2015).
• Evaluate the Effect of Saroglitazar on Postprandial Lipemia in Type 2 Diabetes Mellitus. (2015-2017).
• DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings. (2015 Ongoing).
• Evaluation of the in-vivo efficacy of skin care formulation in terms of reduction in stretch marks, cellulite and inch loss. (2016-2017)
• A single arm study to evaluate the efficacy and safety of topical de-pigmenting agent in healthy human fair skin females (2016-2017)
• A prospective, multicenter, randomized, double-blind, phase III study to evaluate the efficacy and safety of Saroglitazar 4 mg in combination with Rosuvastatin calcium 10 mg in comparison to each component administered alone in patients with dyslipidemia.(2016-2019)
• A drug utilization review of Galvus (vildagliptin) and GalvusMet (vildagliptin plus metformin fixed-drug combination) in type 2 diabetes mellitus.(2016-2018)
• A Prospective Study to analyse Continuous Glucose Monitoring Data in Type 2 Diabetes Mellitus Patients on U 200 Human Premix Insulin (r-DNA Human Insulin Premix 30/70 - 200 IU/mL) (2016-2017)
• Efficacy and tolerability of Fixed Dose Combination of perindopril + amlodipine + indapamide in patients with stage II/III hypertension (TRIPLIXAM) (2016-2019)
• International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan (2016-2018)
• Evaluation of Safety and Efficacy of Hydroxychloroquine Sulfate as an Adjunct to Diet and Exercise to Improve Glycemic Control in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea + Metformin Combination (2017 ongoing)
• A 24-week, randomised, double-blind, double-dummy parallel-group, multi-centre, active-controlled study to evaluate efficacy and safety of remogliflozin etabonate in subjects with type-2 diabetes mellitus. (2017-2019)
• A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients with Homozygous Familial Hypercholesterolemia (HoFH) in India.
• (2018 ongoing).
• RLM-MD-01-A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis (2019 ongoing).
• RLM-MD-03 - A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis (2019 ongoing).
• RLM-MD-04 - A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Gastropares (2019 ongoing)

Awards & Publications : 

Publications and Papers :

•  Significance of reciprocal changes in the anterior chest leads during acute inferior wall infarction – 53 cases. Bombay University Project 1982
• Goldenhar’s Syndrome – Craniofacial dysplasia. Published in Neurology India.1982 June.
• Oral Potassium in the control of mild hypertension. Paper presented at the update in Cardiology II held in Mumbai in 1985.
•  Clinical, biochemical, radiological and pulmonary function correlation of 675 workers exposed to the effluents in a chemical industry. Paper presented at the International Conference in Occupational Medicine in Manila in Dec’85.
•  Cerebrospinal Fluid Haemodynamics. Published in the M.D. News letter of the K.E.M. Hospital.
•  Dygaid - Clinical experience in 50 patients – published in the Bombay Hospital journal vol.35 No. 3. 1995.
• Gatifloxacin in Community Acquired Pneumonia – study presented at the inaugural launch of the new drug – October 2001 in Bombay Hospital Journal.
• The efficacy of chirally pure Amlodipine in reducing hypertension and decreasing peripheral edema in clinical practice involving 20 patients – GP guidelines newsletter– Pune 2002- 2003.
•  Efficacy of S-amlodipine in normotensive angina patients – Journal of Indian Medical Association (JIMA) April 2007.
• A double blind study to determine the clinical efficacy of Chirally pure Pantoprozole in comparison with Racemic Pantoprozole- Published in Indian Journal of Gastro – Enterology 2007.
•  Diabetic Control made easy – THE WEEK, May 2007.
• Malaria – Bombay Indian Medical Association (BIMA) – July 2008.
• Cholesterol and Triglycerides – Indian Menopause Society (IMS) Mirror July 2008.
•  HDL Increasing Strategies – Chapter written in The Association of Physicians of India - (API) Textbook of Medicine. Update – 2008.
•  Fixed dose Perindopril in moderate to severe hypertension – 14th World Congress of Heart Disease 2008 Toronto, Canada.
•  Efficacy and Safety of Cytozen in the Treatment of Nonalcoholic Fatty Liver Disease; A Double-blind, Randomized Placebo-controlled Clinical Trial – Indian Journal of Clinical Practice (IJCP Vol 19 No.5)
•  Blood Pressure control in Diabetic Patients – Chapter written in The Association of Physicians of India - (API)Textbook of Medicine. Update 2009.
•  Management of Hypertension with The Fixed Combination of Perindopril and Amlodipine in Daily Clinical Practice – American Journal of Cardiovascular Drugs– 2009.
•  Effects of a Polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. (Published in Lancet-on-line, March 30, 2009 DOI:10.1016/S01406736(09) 0611-5).
•  Chairman of the Antibiotic Stewardship Committee at Bhatia Hospital which successfully launched the first Guidelines Protocol in India for the use of Antibiotics in Hospital – 2009-2010.
•  Authored a chapter on Treatment of Dyslipidemia in the API Textbook of Medicine -2009 – 2010.
•  Left Pulmonary Artery Hypoplasia presenting with Unilateral Hyprluscent Lung - AJ Sunavala, HP Thacker, JN Khanna – JAPI March 2011.
•  Efficacy and Safety of Lixivaptan for the Treatment of Euvolemic Hyponatremia in the Outpatient Setting: Results of the HARMONY Study -William Abraham, MD1;

Guy Decaux, MD, PhD2; Richard Josiassen, PhD3; Yoram Yagil, MD4; Nelson Kopyt, DO5; Hemant Thacker, MD6; Massimo Manelli, MD7; Daniel G. Bichet, MD8; Cesare Orlandi, MD9 for the HARMONY investigators.*Accepted for Publication in Kidney International in 2011.

•  Vitamin D –A Metabolic modulator-paper presented as the Keynote Address at the Annual Convention of the Indian Medical Association (IMA) Dec 2011.
•  Status Of Vitamin D Deficiency of Patients In A Tertiary Care Centre And Its Co- Morbidities - AACE May 2012.
•  Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal Medicine 2013; 368:1210-1219March 28, 2013.
• Superoxide Dismutase – Evidence Based Perspectives to Target the Redox Dysregulation: Update 2013 – Journal of The Association of Physicians of India in February 2014.
•  Status of Vitamin –D deficiency of patients admitted in Tertiary Care Hospital - Journal of The Association of Physicians of India in February 2014.
•  Status Of Testosterone Levels Of Patients Admitted To A Tertiary Care Hospital - AACE 23rd Annual Scientific and Clinical Congress in Las Vegas, NV, May 14-18, 2014.
•  DRESS Syndrome: Drug Rash with Eosinophilia and Systemic Symptoms - Journal of The Association of Physicians of India -May 2015.
•  Evaluation Series on Safety and Efficacy of Nutritional Supplements (ESSENS) in Newly Diagnosed Hyperglycemia – poster presented at the 75th Session of ADA in Boston, 2015.
• Glycosylated Hemoglobin for Diagnosis of Type 2 Diabetes Mellitus: Progress or Wrong Direction – Research Society for the Study of Diabetes in India (RSSDI) 2015.
•  Efficacy and Safety of Teneligliptin in Asian Diabetics: Pooled Analysis of the Seven Randomised Controlled Clinical Trials- ESICON 2015.
•  Extending Metformin Benefits in patients with Type II Diabetes through Pill Technology. A Systematic Review of nine Pooled Clinical Trials.(Abstract number AATD-0453) - The 9th International Conference on Advanced Technologies & Treatments for Diabetes - Milan 2016.
•  Doxycycline Intravenous- Contemporary Insights & Evidence based Perspectives: A Narrative review – CRITICARE 2016.
• Benefits Of Extended Release Metformin: Systematic Review of the Ongoing Clinical Trials - poster presented at 25th Session of AACE in Orlando 2016.
• Factors Determining The Success And Failure of Type 1 Diabetes Care in Kerala – poster presented at 25th Session of AACE in Orlando 2016.
• Novel Action of Saroglitazar in Patients with Diabetic Dyslipidemia – An observational study. – poster presented at 25th Session of AACE in Orlando 2016.
• Management of Type 2 Diabetes in Western India: Attitudes and Practices among Physicians Leading the Forefront of Diabetes Care - poster presented at the 76th Session of ADA in New Orleans, 2016.
•  Efficacy of Teneligliptin As Monitored With Continuous Glucose monitoring System (CGMS) in Comparison with Standard of Care in Indian Setting - poster Presented at 26th Session of AACE in Austin 2017.
• Improved Short Term and Long Term Outcomes Of Early Insulin Initiation In Type 2 Diabetes Over 10 years at 26th Session of AACE in Austin 2017.
•  Treatment Outcomes With Liraglutide In New Onset Type 2 Diabetes – A Retrospective Analsis at 26th Session of AACE in Austin 2017.
• Meta-synthesis of the Evidence Based Medicine for Teneligliptin: A Systematic Review of 14 Reports – poster presented at the 77th Session of ADA in San Diego, 2017.
• “Glycemic Pentad” keeping Quality of Life (QOL) as a critical factor in the management of diabetes. - Journal of The Association of Physicians of India in July 2017
• 45. The Real Life Effectiveness, Metabolic Effects and Tolerability of Hydroxychloroquine Once Daily in The Treatment of Type 2 Diabetes Mellitus at 27th Session of AACE Boston, MA 2018
•  Correlates and Association of Vitamin D levels in Patients Diagnosed with H1N1 - Swine Flu Virus at 27th Session of AACE Boston, MA 2018
•  Evidence To Experience For The Improved Glycemic Control With Once weekly Dulaglutide Evaluated By Continuous Glucose Monitoring – Case Report at 28th Session of AACE Boston, MA 2018
•  Acceptance And Vaccination Rates Of Influenza And Pneumococcal Vaccine Among Type 2 Diabetics In The Community. 28th Session of AACE Boston, MA 2018
•  Continuous Glucose Monitoring Guided Assessment of Concentrated U200 r-DNA Human Premix 30/70 Insulin. 78th Scientific Sessions 2018;Orlando, Florida
•  Efficacy of a Basal-Plus Regimen 78th Scientific Sessions ADA 2018;Orlando, Florida
• 51. Ambulatory Glucose Profiling (AGP) Helps Bridge The Glycemic Gap Between Conventional Sugars And HbA1C Thus Facilitating Better Control in Younger Patients And Those With Unpredictable Lifestyles at 29th Session of AACE Los Angeles, CA 2019.
•  Consistency and Predictability of Control of Glycemic Variability with U200 (Concentrated r-DNA Human Insulin Premix 30/70 - 200 IU/mL) in Type 2 Diabetes Mellitus Patients at79th Scientific Sessions 2019; San Francisco, California
•  Baseline Characteristics of Patients in the First Pan-India, Prospective, Longitudinal Study to Assess Management and Outcomes of T2D in Real-World Settings—LANDMARC at79th Scientific Sessions 2019; San Francisco, California
•  Real-World Effectiveness of a Blood Sugar Monitor and Companion Digital Therapeutic Combination in Improving Blood Glucose Levels among People with Diabetes in India at 79th Scientific Sessions 2019; San Francisco, California
•  Baseline Characteristics of participants in the LANDMARC trail: A 3-year , Pan-India, prospective, longitudinal study to assess management and real-world outcomes of diabetes mellitus on 8th Feb 2021 Research Article in Wiley.
•  Cardio-renal-metabolic Care in T2DM with a Harmonious Blend of SGLT-2i/DPP-4i Fixed-drug Combination- Jun 2022 RSSDI.
•  Expert consensus on the role of nutraceuticals in improving patient care standards – International Journal of Advanced Research in Medicine 2022, Vol. 4, Issue 2, Part B

Extra Curricular Honours : 

• 1972-74 Awarded the prize for the Best Speaker of Jai Hind College in addition to numerous 1st prizes in debating and elocution competitions at the Jai Hind college.
• 1972-78 Awarded many prizes at the Inter Collegiate and Inter University level in the field of Public Speaking.
• 1975-78 Bagged innumerable prizes including the Best Speaker’s in the different public speaking contests at K.E.M. Hospital.
• 1972-74 Founder of English Association of Jai Hind College.
• 1973-74 Elected to the governing body of the Bombay University Debating Society.
• 1974-78 Programming Host of the Bombay Television’s Young World series.
• 1978-85 Managing Committee Member and subsequently Hon. Gen. Secretary of the
• Medical Welfare Trust of Bombay.
• 2002-03 Felicitated and Conferred the distinction of Best Alumnus of Jai Hind College in the field of Medicine
• 2010-11 Conferred the “Hall of Fame” Distinction – A Meritorious Recognition by St Xavier’s Boys’ Academy alumni association for distinguished students.